Rivero-Ayerza M et al. (2006) Effects of cardiac resynchronization therapy on overall mortality and mode of death: a meta-analysis of randomized controlled trials. Eur Heart J 27: 2682–2688
Cardiac resynchronization therapy (CRT) improves symptoms, quality of life and exercise capacity in patients with advanced heart failure; however, studies to date have been underpowered to assess the effects of CRT on mortality. This meta-analysis by Rivero-Ayerza et al. combines data from 2,371 patients taken from 5 studies that compared the effect on survival of CRT alone versus optimum pharmacologic therapy. The mean age of the study populations included in this meta-analysis ranged from 64 years to 68 years, and the majority of patients were male.
During the mean follow-up period of 18.4 months (range 3.0–29.4 months), patients who received CRT alone had a lower all-cause mortality than those receiving pharmacologic therapy (16.9% vs 20.7%; odds ratio [OR] 0.71, 95% CI 0.57–0.88; P = 0.002). The observed survival benefit of CRT alone was largely attributable to a reduction in death from progressive heart failure (6.7% vs 9.7%; OR 0.62, 95% CI 0.45–0.84; P = 0.003). This reduced progressive heart failure mortality is unsurprising as CRT directly moderates myocardial function and heart failure profile. Rates of sudden cardiac death were similar in the two groups (6.4% vs 5.9%; OR 1.04; P = 0.84).
Despite the observed benefits of CRT, mortality remained high for patients with advanced heart failure. The authors of this study suggest that adding a defibrillator function to a CRT device is likely to further increase survival, and that this warrants further investigation.
Rights and permissions
About this article
Cite this article
Cardiac resynchronization therapy lowers mortality in advanced heart failure. Nat Rev Cardiol 4, 67 (2007). https://doi.org/10.1038/ncpcardio0760
Issue Date:
DOI: https://doi.org/10.1038/ncpcardio0760